Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Fluoguide reported positive phase 2 data while Expres2ion presented poor phase 3 data. 2Curex launched two products and Zealand Pharma announced designation of priority review by the US FDA. Finally, two companies reported earnings and one more will follow this week.
The past week was full of interesting news with 11 of the 20 listed Danish biotech companies publishing news. 10 of the 20 companies had a positive share price development the past week and 9 companies have a positive share price performance year to date. Saniona overtook Fluoguide as the best performing stock year-to-date. SynAct Pharma was until today the best performing stock the 12 months.
Company news the past week
Ascendis Pharma
Ascendis Pharma is set to report earnings on September 5 (Link). Analysts expects 37.35 MEUR in revenue and a loss of EUR 2.59 per share.
Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million (Link)
Cessatech
No news the past week
CS MEDICA A/S Achieves Milestone with Patent on Nasal Night Spray (Link)
No news the past week
Evaxion Biotech
Evaxion announces Executive Management Changes to strengthen the AI-strategy (Link)
Expres2ion
ExpreS2ion Biotechnologies: Phase III secondary endpoint data announced for the COVID-19 booster vaccine candidate (Link)
Fluoguide
FluoGuide A/S issues warrants to the investors participating in the directed share issue (Link)
FluoGuide completes patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer (Link)
FluoGuide reports further positive interim data from phase IIa trial of FG001 in head & neck cancer (Link)
FluoGuide A/S publishes interim report for the period January – June 2023 (Link)
Genmab
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference (Link)
Gubra
Gubra resumes its share buy-back programme to hedge incentive scheme obligations (Link)
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
Saniona publishes its interim report for the second quarter of 2023 (Link)
Scandion Oncology
No news the past week
SynAct Pharma
No news the past week, but has today annonced that the phase 2B triels did not meet the primary endpoint (Link)
ViroGates
No news the past week
Zealand Pharma
Sale of shares in Zealand Pharma A/S by a board member (Link)
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism (Link)
Y-mAbs Therapeutics
No news the past week
2cureX
2cureX launches its first two IndiTreat® products CE-marked under the new IVD Regulation (Link)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
On average, the Danish biotech stocks delivered a positive share price performance last week of 0.2%. Notably, the three best performing companies did not report any news during the week. Fluoguide completed patient enrollment and treatment in FG001 phase llb clinical trial in aggressive brain cancer and presented positive interim data from phase IIa trial of FG001 in head & neck cancer. The worst performer of the week became Expres2ion after presenting Phase III secondary endpoint data for the COVID-19 booster vaccine candidate. The reason behind the falling share price was that Expression Biotech’s partner Bavarian Nordic saw a lower level of neutralizing antibodies for its COVID-19 vaccine candidate in the completed Phase 3 study than for the vaccines it was compared to in the study. The best stocks year-to-date include Curasight, Fluoguide, and Saniona after soaring 121-155%. Overall, the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 6.4%. However, it is driven by the few companies delivering very positive returns.
Read more about Curasight (in Danish): Et succesfuldt kvartal for Curasight med mere i vente
Overview of share price developments the past week, year-to-date and last twelve months
